CS
ADMS

Credit Suisse’s Adamas Pharmaceuticals ADMS Stock Holding History

Credit Suisse’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,995
Closed -$107K – 4404
2019
Q3 		$107K Buy
+20,995
New +$130K ﹤0.01% 3961
2019
Q2 		– Sell
-21,149
Closed -$151K – 4285
2019
Q1 		$151K Buy
21,149
+2,353
+13% +$21.2K ﹤0.01% 3806
2018
Q4 		$161K Buy
18,796
+2,001
+12% +$26K ﹤0.01% 3706
2018
Q3 		$337K Sell
16,795
-18,712
-53% -$439K ﹤0.01% 3473
2018
Q2 		$917K Buy
35,507
+8,764
+33% +$243K ﹤0.01% 3077
2018
Q1 		$640K Buy
26,743
+1,408
+6% +$44.4K ﹤0.01% 3231
2017
Q4 		$859K Sell
25,335
-7,543
-23% -$211K ﹤0.01% 3108
2017
Q3 		$697K Buy
+32,878
New +$603K ﹤0.01% 3344
2016
Q4 		– Sell
-16,817
Closed -$276K – 4287
2016
Q3 		$276K Sell
16,817
-18,299
-52% -$278K ﹤0.01% 3687
2016
Q2 		$532K Sell
35,116
-8,566
-20% -$141K ﹤0.01% 3384
2016
Q1 		$632K Buy
43,682
+36,018
+470% +$607K ﹤0.01% 3077
2015
Q4 		$217K Sell
7,664
-9,250
-55% -$156K ﹤0.01% 3847
2015
Q3 		$283K Sell
16,914
-1,139
-6% -$25.9K ﹤0.01% 3755
2015
Q2 		$473K Buy
+18,053
New +$351K ﹤0.01% 3765

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Credit Suisse's ADMS Position: Q4 2019 in Review

Credit Suisse sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 20,995 shares — an estimated $107K sold.

Credit Suisse first reported a position in ADMS in Q2 2015 and held it in 14 quarters. The position peaked at $917K in Q2 2018. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Credit Suisse reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 20,995 Adamas Pharmaceuticals shares in Q4 2019, an estimated $107K.
  • Credit Suisse first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 14 quarters.
  • Credit Suisse's Adamas Pharmaceuticals position peaked at $917K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.